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Non-steroidal anti-inﬂammatory drugs (NSAIDs) are at the cornerstone of treatment for osteoarthritis
(OA). In recent years, the widespread use of oral NSAIDs has been called into question due to the
appearance of signiﬁcant upper gastrointestinal (GI) complications and cardiovascular (CV) adverse
events (AEs). However, NSAIDs are non-homogeneous, and there are noticeable differences between
them in AE risk for GI and CV events. Nevertheless, if properly prescribed oral NSAIDs can provide an
effective and safe treatment for OA in real-life situations. The identiﬁcation of patients with signiﬁcant
CV and/or GI risk is critical, and the European Society for Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis (ESCEO) treatment algorithm provides guidance on appropriate treatments for OA
patients with elevated risk. Among non-selective NSAIDs, ibuprofen and naproxen seem preferable to
diclofenac, the latter being associated with higher CV risk. Recommendation has been made by some
that naproxen may be the preferred agent in patients at high CV risk because of its lower risk of CV
events. Low dose celecoxib (200 mg/day) is also associated with a lower risk of CV events compared
with other coxibs. In addition, drugs with a demonstrated low GI risk proﬁle may be of beneﬁt, such as
coxibs and nabumetone. Among patients who fail to respond adequately to sequential ESCEO algorithm
Step 1 and Step 2 treatments, the short-term use of weak opioids, such as tramadol, for severely
symptomatic OA patients is recommended. Although studies exploring the efﬁcacy of tramadol in OA
are limited, there is good evidence that tramadol works if prescribed properly. The sustained-release
(SR) formulation of tramadol is preferred as it avoids the peak plasma concentrations reached
with immediate-release tramadol, and is believed to reduce the incidence of AEs. Furthermore, slow
upwards titration of tramadol SR is recommended to improve tolerability and minimize treatment
discontinuations.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm
recommends oral non-steroidal anti-inﬂammatory drugs (NSAIDs)
for Step 2 advanced pharmacological management of knee osteo-
arthritis (OA) if Step 1 treatment shows inadequate efﬁcacy and
the patient is still symptomatic, or in patients presenting withr HS Journals, Inc. This is an open
lar; GI, gastrointestinal; MI,
GIC, upper gastrointestinalmoderate-severe pain [1]. Oral NSAIDs are universally recommen-
ded across the international and national guidelines (Table 1) in
patients with persistent symptoms that have not responded
adequately to paracetamol with or without topical NSAIDs or, in
the ESCEO recommendations, to symptomatic slow-acting drugs
for osteoarthritis (SYSADOAs) [1–5]. Oral NSAIDs have a moderate
effect on pain relief, with an effect size (ES) of 0.29 (95% CI:
0.22–0.35) that is greater than that of paracetamol (ES ¼ 0.14,
95% CI: 0.05–0.22) [6]. Use of oral NSAIDs has been associated with
greater efﬁcacy in patients with more severe knee and hip OA
accompanied by a higher degree of patient preference compared
with paracetamol [7]. Cyclo-oxygenase-2 (COX-2) selective, parti-
ally selective, or non-selective oral NSAIDs are similarly effective in
controlling pain [8]. Thus, drug choice is dictated by their safetyaccess article under the CC BY-NC-ND license
Table 1
Recommendations for the use of oral non-steroidal anti-inﬂammatory drugs (NSAIDs) for osteoarthritis
Guideline committee OA location Recommendation for oral NSAIDs
European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO)
Knee Recommended when paracetamol or SYSADOAs and/or topical NSAIDs are
not adequately effective
European League Against Rheumatism (EULAR) Knee Consider in patients unresponsive to paracetamol
American College of Rheumatology (ACR) Hand, knee, and hip Conditionally recommended for initial therapy; strongly recommended in
knee OA patients unresponsive to paracetamol
Osteoarthritis Research Society International (OARSI) Knee Appropriate for individuals without relevant co-morbidities; uncertain for
those with moderate co-morbidity risk
National Institute for Health and Care Excellence (NICE) Hand, knee, and hip Use when paracetamol and/or topical NSAIDs are ineffective, or in addition to
paracetamol or topical NSAIDs when insufﬁcient pain relief is achieved
OA, osteoarthritis; NSAIDs, non-steroidal anti-inﬂammatory drugs; SYSADOAs, symptomatic slow-acting drugs for osteoarthritis.
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itant diseases and medical conditions [1].
Among patients who fail to respond adequately to sequential
Step 1 and Step 2 treatments, the ESCEO algorithm recommends
the short-term use of weak opioids, such as tramadol, as a last
pharmacological treatment before recourse to surgery [1]. Sim-
ilarly, the American College of Rheumatology (ACR) recommends
tramadol as an appropriate analgesic in OA pain when non-opioid
analgesics, coxibs, and non-selective NSAIDs are poorly tolerated,
ineffective, or contraindicated [3]. The antidepressant duloxetine is
also proposed by the ESCEO at Stage 3 in treatment [1]; however,
the combination of tramadol and duloxetine is not recommended
due to their similar central mechanism of action.Fig. 1. Pooled relative risks and 95% CIs of upper gastrointestinal complications
associated with the use of individual NSAIDs [13]. Vertical bars denote 95% CIs.
(Reproduced with permission Castellague et al. [13]; reproduction granted under
Creative Commons Attribution Noncommercial license.)Examination of the evidence base for oral NSAID safety
The NSAIDs are non-homogeneous as a drug class, and there
are vast differences between individual drugs in terms of adverse
event (AE) risk for gastrointestinal (GI) and cardiovascular (CV)
complications. Thus, the beneﬁt-risk balance of individual NSAIDs
is mainly driven by their GI and CV safety proﬁle. The US Food and
Drug Administration (FDA) has issued a “black box” safety warning
for the entire oral NSAID drug class highlighting the potential for
increased risk of CV events and GI bleeding associated with their
use [9].
Upper GI complications
Oral NSAID treatment is associated with a 3-fold to 5-fold
increase in the risk of upper GI complications (UGIC), including
peptic ulcer perforation, obstruction, and bleeding [10,11]. GI side
effects from NSAIDs arise from both topical injury and COX-1
inhibition, which is present even when a parenteral formulation is
used, and data indicate a similar safety and tolerability proﬁle with
intravenous and oral ibuprofen, for example [12]. While COX-2
selective agents are associated with fewer GI ulcer complications,
there is still an increased risk of UGIC [13]. Systematic review and
meta-analyses have identiﬁed considerable variability in the risk of
UGIC among individual oral NSAIDs as used in clinical practice
[13,14]. Piroxicam, ketorolac, and azapropazone were associated
with the highest relative risk of UGIC, while aceclofenac, celecoxib,
and ibuprofen were associated with the lowest relative risk, and an
intermediate level of risk was found for all other NSAIDs included
in the review (Fig. 1) [13]. The high risk of UGIC with indomethacin
may be attenuated by use of acemetacin, a pro-drug for indome-
thacin. Acemetacin is less active on the COX-1 enzyme in the
gastric mucosa, and was found in a study to exhibit similar efﬁcacy
in OA with around one-third the incidence of GI AEs found with
indomethacin [15]. Acemetacin was also demonstrated to have
similar efﬁcacy and safety to celecoxib in knee OA treatment over
6 weeks [16]. Nabumetone is an NSAID that exhibits equivalentefﬁcacy to many others but with a comparatively good safety
proﬁle [17], with 10-fold fewer GI AEs (perforations, ulcers, or
bleedings) reported across clinical studies compared with other
NSAIDs [18,19].
High daily doses of several NSAIDs are associated with a 2-fold
to 3-fold increase in the relative risk of UGIC compared with
low–medium doses, with the exception of celecoxib for which no
dose–response relationship was found [13]. These ﬁndings provide
a strong rationale for the use, whenever possible, of low drug
dosages for the shorter period of time to minimize GI toxicity.CV complications
The association of NSAIDs with increased CV risk is a complex
issue, but there is today little doubt that all oral NSAIDs, selective,
and non-selective, have the potential to increase the risk of serious
CV events. The coxib and traditional NSAID trialists (CNT) collab-
oration performed a meta-analysis of 639 RCTs, and found that
major vascular events were increased by about one-third with a
coxib [rate ratio (RR): 1.37; 95% CI: 1.14–1.66; p ¼ 0.0009] or
diclofenac (150 mg/day) (RR: 1.41; 95% CI: 1.12–1.78; p ¼ 0.0036)
compared with placebo (Fig. 2) [20]. This was largely due to an
increase of around three-quarters in the risk of major coronary
events. Ibuprofen (2400/day) also signiﬁcantly increased major
coronary events (RR: 2.22; 95% CI: 1.10–4.48; p ¼ 0.0253) but not
major vascular events (RR: 1.44; 95% CI: 0.89–2.33; p ¼ 0.14).
In contrast, high dose naproxen (1000 mg/day) was associated
with less vascular risk than other NSAIDs (RR: 0.93; 95% CI: 0.69–
1.27; p ¼ 0.66) and no increase in major coronary events (RR: 0.84;
95% CI: 0.52–1.35; p ¼ 0.48) [20]. There was no evidence that any
NSAID signiﬁcantly increased the risk of stroke, although an earlier
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Fig. 2. Effects of coxib and traditional NSAID treatment on risk of major vascular events [20]. Major vascular events includes non-fatal myocardial infarction (MI), coronary
death, MI or coronary heart disease, non-fatal stroke, stroke death, any stroke, other vascular death. CI, conﬁdence interval; RR, rate ratio. (Adapted from Bhala et al. [20].)
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ibuprofen (RR: 3.36, 95% CI: 1.00–11.6) [21]. While the vascular
risks of different coxib regimens appeared similar at the most
frequently studied daily doses, there was a trend for lower risk
with lower celecoxib doses; although the vascular effects of the
most widely used coxib regimen, celecoxib 200 mg/day, were
statistically uncertain [20]. Vascular risk is likely related to the
degree of COX-2 inhibition, which increases with dose, suggesting
a dose-dependent effect.
The risk of acute myocardial infarction (MI) with individual
coxibs and non-selective oral NSAIDs was also previously assessed
in a large nested case–control study that included over 2,356,885
person-years of follow-up and 15,343 cases of acute MI [22].
Indomethacin, sulindac, and meloxicam were associated with the
highest increased risk of acute MI, while nabumetone was asso-
ciated with the lowest risk of acute MI (Fig. 3). Among the coxibs,
rofecoxib was associated with the highest risk, while celecoxib (all
dosages) and low dose valdecoxib (20 mg/day) were associated
with the lowest risk of acute MI [22].Guidance on use of NSAIDs in real-life OA patients
The choice of NSAID to use in clinical practice depends on
individual patient characteristics and medical history. Several
patient factors have been identiﬁed to increase the risk of UGIC,0.6 0.8
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Fig. 3. Risk for acute myocardial infarction with non-selective NSAIincluding advanced age, a history of GI ulcer, and concomitant
treatment with corticosteroids, aspirin, or anticoagulants (Fig. 4)
[23,24]. The ESCEO recommends that patients are assessed for risk
factors and the risk:beneﬁt ratio of treatment is determined before
making treatment decisions. Patient preference is an important
consideration, for example, of dosing regimen whether once-daily
or more frequent dosing is desirable.
GI complications associated with oral NSAID use are the most
common serious adverse drug reactions in the United States.
A large majority of NSAID-associated GI AEs are asymptomatic
until a complication occurs, i.e., they are not preceded by mild side
effects such as abdominal pain and vomiting [25]. The use of
concomitant gastroprotective agents such as proton pump inhib-
itors (PPIs) are the most commonly recommended treatments to
reduce the risk of GI complications with non-selective NSAIDs.
Moreover, concomitant use of high dose of famotidine or miso-
prostol can also reduce the occurrence of gastric ulcer complica-
tions by 50–60% [26]. Among patients with a prior history of ulcer
bleeding, treatment with diclofenac plus omeprazole was shown
to be as safe as treatment with celecoxib, with respect to the
prevention of recurrent bleeding [27].
While coxibs are associated with a lower risk of UGIC compared
with non-selective NSAIDs, there is still a signiﬁcant increase in
risk compared with placebo [20]. The ESCEO algorithm recom-
mends that in patients with low (normal) GI risk, it should be
considered to prescribe either a non-selective NSAID with or1.0 1.2 1.4 1.6 1.8
erence
ote use
 rao (OR) for acute myocardial infarcon (95% CI)
2.22.0
Ds and COX-2 inhibitors [22]. (Adapted from Singh et al. [22].)
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Fig. 4. Clinical risk factors for gastrointestinal gastropathy [24]. (Adapted from
Hunt et al. [24].
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of the clinician. In patients with high GI risk, which includes
patients receiving concomitant low dose aspirin, non-selective
NSAIDs should be avoided and COX-2 selective NSAIDs should be
co-prescribed with a PPI [28] (Table 2).
Regarding CV risk associated with oral NSAID use, early
evidence suggested that the relative risk of CV events increased
with increased baseline CV risk [29]; although a recent and
comprehensive meta-analysis found that the proportional increase
in risk was similar irrespective of baseline risk [20]. Thus, these
drugs should be avoided in high CV risk patients and probably
other non-selective NSAIDs as well. Ibuprofen should not be used
with concomitant low dose aspirin due to clinically relevant
pharmacological interaction [30]. Naproxen is the exception, and
may be the preferred agent if an NSAID is required in patients at
high CV risk, because of its lower risk of CV events [20,31]. The
lower risk of CV thrombovascular events associated with naproxen
may be due to its sustained suppression of platelet aggregation
[20]. In a 2012 report, the European Medicines Agency (EMA)
stated that naproxen may be associated with a lower risk of
arterial thrombotic events than COX-2 inhibitors and other NSAIDs
[32]. In addition, following a review of CV safety, the EMA issued a
warning for oral diclofenac treatment not to be prescribed to
patients with ischemic heart disease, peripheral arterial disease,
cerebrovascular disease, or established congestive heart failure,
which was subsequently endorsed by the European Commission
[33]. The ESCEO and ACR recommend that oral NSAID use is
avoided in patients with increased renal risk, such as chronic
kidney disease with estimated glomerular ﬁltration rate below
30 cc/min [1,3].
Due to the risk of GI and CV events, the product information for
all NSAIDs recommends that these medicines be used at the lowest
effective dose for the shortest period of time necessary to control
symptoms [32]. The ESCEO algorithm recommends that oral
NSAIDs may be used intermittently or continuously in longerTable 2
ESCEO recommendations for Step 2 advanced pharmacological management of persiste
Intermittent or continuous (longer cycles) oral NSAIDs
Normal GI risk Increased GI riska Increased
Non-selective NSAID with PPI COX-2 selective NSAID with PPI Prefer nap
COX-2 selective NSAID (consider PPI) Avoid non-selective NSAIDs Avoid high
Caution w
Avoid COX
COX-2, cyclooxygenase-2; CV, cardiovascular; GI, gastrointestinal; NSAID, non-steroidal
(Adapted from Bruyere et al. [1].)
a Including use of low dose aspirin.
b With glomerular ﬁltration rate o30 cc/min, caution in other cases.cycles rather than in chronic use, because of safety concerns and
a lack of long-term trials [1]. A recent short-term trial of low dose
celecoxib (200 mg/day) found that continuous treatment with
celecoxib over 22 weeks was signiﬁcantly more effective than
intermittent use in preventing OA ﬂares of the hip and knee
without an increase in overall AEs including GI disorders and
hypertension [34]. However, the select population included in the
trial had low CV and GI risks and, therefore, is not representative of
the general OA patient population.
In the event of insufﬁcient control of symptoms with an NSAID,
the combination of NSAIDs is not recommended by the ESCEO task
force, as there is no evidence of additional beneﬁt, and an
increased risk of AEs, with additional cost of treatment. While
switching NSAIDs may provide some beneﬁt, the ESCEO task force
does not recommend multiple successive rounds of NSAIDs before
considering other treatment options. If the patient is still sympto-
matic despite use of NSAIDs, the ESCEO algorithm recommends
intra-articular treatment, or recourse to short-term weak opioids,
e.g., tramadol [1].Pharmacological treatment with weak opioids
Among OA patients who fail to respond adequately to pharma-
cological treatments, including oral NSAIDs, the ESCEO algorithm
recommends the short-term use of weak opioids, such as trama-
dol, as one of the last pharmacological treatments before recourse
to surgery [1]. Tramadol is a synthetic, centrally acting analgesic
with opioid agonist properties that acts on the neurotransmission
of norepinephrine and serotonin. In addition, tramadol modiﬁes
the transmission of pain impulses by inhibition of monoamine
reuptake. Tramadol rarely causes the AEs of respiratory depression
and physical dependence commonly associated with conventional
opioid drugs, since its analgesic effects are through both weak
opioid and non-opioid mechanisms [35]. Tramadol is not attrib-
uted with the GI and CV AEs associated with NSAIDs [36].
However, the use of tramadol may be impeded by non-serious
AEs, predominantly nausea and headache, resulting in treatment
withdrawal and sub-optimal pain management [37,38]. Sustained
release (SR) formulations of tramadol may improve tramadol
tolerability and reduce the incidence of AEs [39]. SR formulations
are associated with prolonged effective plasma levels of tramadol,
while preventing the high plasma peaks associated with AEs seen
with the immediate-release formulations [39,40]. In addition,
multiple-unit SR capsule formulation produces a smoother and
extended tramadol plasma concentration proﬁle compared with
single-unit SR tablets due to a more gradual release of tramadol
[39]. Further, the slow upward titration of SR tramadol is recom-
mended to minimize AEs and premature treatment discontinua-
tions [41]. The dose titration of multiple-unit SR tramadol leads tont symptoms in patients with osteoarthritis using oral NSAIDs [1]
CV risk Increased renal risk
roxen Avoid NSAIDsb
dose diclofenac and ibuprofen (if on low dose aspirin)
ith other non-selective NSAIDs
-2 selective NSAIDs
anti-inﬂammatory drug; PPI, proton pump inhibitor.
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Fig. 5. Effect of dose titration of multiple-unit SR tramadol (50–100 mg bid, over 7 days) on incidence of AEs leading to treatment discontinuations. (Adapted from Tagarro
et al. [41].)
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discontinuations (Fig. 5) [41].
A Cochrane review of RCTs showed that the efﬁcacy of tramadol
in relieving pain and improving function in knee OA is small but
signiﬁcant, although AEs are signiﬁcantly increased over placebo
and may lead to treatment withdrawal [36]. Treating OA patients
with short-term tramadol may decrease pain, reduce stiffness and
improve function, and overall well-being [36]. In a placebo-
controlled study of tramadol in patients with OA, patients did
signiﬁcantly better with tramadol than with placebo [42].Conclusions
NSAIDs are non-homogeneous, and there are vast differences in
AE risk for GI and CV events. Nonetheless, if properly prescribed
oral NSAIDs can provide an effective and safe treatment for OA.
The identiﬁcation of patients at risk of signiﬁcant CV and/or GI side
effects is crucial, and the ESCEO algorithm provides guidance on
appropriate treatments for OA patients with elevated risk. Low
dose celecoxib (100–200 mg/day) is associated with a lower risk of
CV events compared with other coxibs and diclofenac. Among
non-selective NSAIDs, ibuprofen and naproxen are preferable to
diclofenac. In addition, other drugs with a demonstrated low-risk
AE proﬁle may be of beneﬁt such as nabumetone and acemetacin,
which shows similar efﬁcacy and safety to celecoxib. Intermittent
cycles of treatment are usually preferable than continuous admin-
istration, to minimize the risk of AEs. The combination of NSAIDs is
discouraged as this provides no additional beneﬁt, with an
increased risk of AEs and additional cost. Multiple successive
rounds of NSAIDs should also be avoided in patients with persis-
tent symptoms before considering subsequent steps in the ESCEO
recommended treatment algorithm.
The short-term use of soft weak opioids, such as tramadol, may
be considered for severely symptomatic OA patients. Although
studies of tramadol are limited in OA, there is good evidence that
tramadol works if prescribed properly. The SR formulation of
tramadol is preferred as it avoids the peak plasma concentrations,
and consequently reduces the incidence of side effects. Further-
more, slow upwards titration of SR tramadol is recommended to
improve tolerability and minimize treatment discontinuations due
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